Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice.
Achondroplasia
Assessments
Clinical practice
Early experience
Guidance
Management
Monitoring
Practicalities
Vosoritide
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
26 Oct 2023
26 Oct 2023
Historique:
received:
01
06
2023
accepted:
03
10
2023
medline:
26
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
aheadofprint
Résumé
Vosoritide is the first precision medical therapy approved to increase growth velocity in children with achondroplasia. Sharing early prescribing experiences across different regions could provide a framework for developing practical guidance for the real-world use of vosoritide. Two meetings were held to gather insight and early experience from experts in Europe, the Middle East, and the USA. The group comprised geneticists, pediatric endocrinologists, pediatricians, and orthopedic surgeons. Current practices and considerations for vosoritide were discussed, including administration practicalities, assessments, and how to manage expectations. A crucial step in the management of achondroplasia is to determine if adequate multidisciplinary support is in place. Training for families is essential, including practical information on administration of vosoritide, and how to recognize and manage injection-site reactions. Advocated techniques include establishing a routine, empowering patients by allowing them to choose injection sites, and managing pain. Patients may discontinue vosoritide if they cannot tolerate daily injections or are invited to participate in a clinical trial. Clinicians in Europe and the Middle East emphasized the importance of assessing adherence to daily injections, as non-adherence may impact response and reimbursement. Protocols for monitoring patients receiving vosoritide may be influenced by regional differences in reimbursement and healthcare systems. Core assessments may include pubertal staging, anthropometry, radiography to confirm open physes, the review of adverse events, and discussion of concomitant or new medications-but timing of these assessments may also differ regionally and vary across institutions. Patients and families should be informed that response to vosoritide can vary in both magnitude and timing. Keeping families informed regarding vosoritide clinical trial data is encouraged. The early real-world experience with vosoritide is generally positive. Sharing these insights is important to increase understanding of the practicalities of treatment with vosoritide in the clinical setting.
Identifiants
pubmed: 37882884
doi: 10.1007/s12325-023-02705-9
pii: 10.1007/s12325-023-02705-9
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
Coi A, Santoro M, Garne E, et al. Epidemiology of achondroplasia: a population-based study in Europe. Am J Med Genet A. 2019;179:1791–8.
doi: 10.1002/ajmg.a.61289
pubmed: 31294928
Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020;182A:2297–316.
doi: 10.1002/ajmg.a.61787
Rousseau F, Bonaventure J, Legai-Mallet L, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994;371:252–4.
doi: 10.1038/371252a0
pubmed: 8078586
Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78:335–42.
doi: 10.1016/0092-8674(94)90302-6
pubmed: 7913883
Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370:162–72.
doi: 10.1016/S0140-6736(07)61090-3
pubmed: 17630040
Hoover-Fong J, Cheung MS, Fano V, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone. 2021;146:115872.
doi: 10.1016/j.bone.2021.115872
pubmed: 33545406
Wright MJ, Irving M. Clinical management of achondroplasia. Arch Dis Child. 2012;97:129–34.
doi: 10.1136/adc.2010.189092
pubmed: 21460402
Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14:1.
doi: 10.1186/s13023-018-0972-6
pubmed: 30606190
pmcid: 6318916
Maghnie M, Semler O, Guillen-Navarro E, et al. Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. Orphanet J Rare Dis. 2023;18:56.
doi: 10.1186/s13023-023-02652-2
pubmed: 36922864
pmcid: 10015810
Savarirayan R, Irving M, Harmatz P, et al. Growth parameters in children with achondroplasia: a 7-year, prospective, multinational, observational study. Genet Med. 2022;24:2444–52.
doi: 10.1016/j.gim.2022.08.015
pubmed: 36107167
Horton WA, Rotter JI, Rimoin DL, Scott CI, Hall JG. Standard growth curves for achondroplasia. J Pediatr. 1978;93:435–8.
doi: 10.1016/S0022-3476(78)81152-4
pubmed: 690757
Merker A, Neumeyer L, Hertel NT, et al. Growth in achondroplasia: development of height, weight, head circumference, and body mass index in a European cohort. Am J Med Genet A. 2018;176:1723–34.
doi: 10.1002/ajmg.a.38853
pubmed: 30070757
Merker A, Neumeyer L, Hertal NT, et al. Development of body proportions in achondroplasia: sitting height, leg length, arm span, and foot length. Am J Med Genet A. 2018;176:1818–29.
doi: 10.1002/ajmg.a.40356
Hoover-Fong JE, Schulze KJ, Alade AY, et al. Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study—a multi-center retrospective cohort study of achondroplasia in the US. Orphanet J Rare Dis. 2021;16:522.
doi: 10.1186/s13023-021-02141-4
pubmed: 34949201
pmcid: 8697459
Hoover-Fong J, Scott CI, Jones MC, AAP Committee on Genetics. Health supervision for people with achondroplasia. Pediatrics. 2020;145:e20201010.
doi: 10.1542/peds.2020-1010
pubmed: 32457214
Alade Y, Tunkel D, Schulze K, et al. Cross-sectional assessment of pain and physical function in skeletal dysplasia patients. Clin Genet. 2013;84:237–43.
doi: 10.1111/cge.12045
pubmed: 23106480
Constantinides C, Landis SH, Jarrett J, Quinn J, Ireland PJ. Quality of life, physical functioning, and psychosocial function among patients with achondroplasia: a targeted literature review. Disabil Rehabil. 2022;44:6166–78.
doi: 10.1080/09638288.2021.1963853
pubmed: 34403286
Maghnie M, Semler O, Guillen-Navarro E, et al. Health-related quality of life (HRQoL) in achondroplasia: findings from a multinational, observational study. Mol Genet Metabol. 2021;132:S127–8.
doi: 10.1016/S1096-7192(21)00280-8
Nahm NJ, Mackenzie WS, Mackenzie WG, et al. Achondroplasia natural history study (CLARITY): 60-year experience in orthopedic surgery from four skeletal dysplasia centers. Orphanet J Rare Dis. 2023;18(1):139.
doi: 10.1186/s13023-023-02738-x
pubmed: 37280669
pmcid: 10246371
Leiva-Gea A, Delgado-Rufino FB, Queipo-de-Llano A, Mariscal-Lara J, Lombardo-Torre M, Luna-González F. Staged upper and lower limb lengthening performing bilateral simultaneous surgery of the femur and tibia in achondroplastic patients. Arch Orthop Trauma Surg. 2020;140:1665–76.
doi: 10.1007/s00402-020-03360-3
pubmed: 32048016
Hosny GA. Limb lengthening history, evolution, complications and current concepts. J Orthop Traumatol. 2020;21:3.
doi: 10.1186/s10195-019-0541-3
pubmed: 32140790
pmcid: 7058770
Yorifuji T, Higuchi S, Kawakita R. Growth hormone treatment for achondroplasia. Pediatr Endocrinol Rev. 2018;16(Suppl 1):123–8.
pubmed: 30378790
Harada D, Namba N, Hanioka Y, et al. Final adult height in long-term growth hormone-treated achondroplasia patients. Eur J Pediatr. 2017;176:873–9.
doi: 10.1007/s00431-017-2923-y
pubmed: 28501952
pmcid: 5486548
Lorget F, Kaci N, Peng J, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91:1108–14.
doi: 10.1016/j.ajhg.2012.10.014
pubmed: 23200862
pmcid: 3516592
Savarirayan R, Irving M, Bacino CA, et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Eng J Med. 2019;381:25–35.
doi: 10.1056/NEJMoa1813446
Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396:684–92.
doi: 10.1016/S0140-6736(20)31541-5
pubmed: 32891212
Hoover-Fong J, Savarirayan R, Tofts L, et al. Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 35 years: update from phase 3 extension study. Genet Med. 2023;1(1):100222.
Cormier-Daire V, Cohen S, Edouard T, et al. Real-world experience with vosoritide for achondroplasia: interim findings from an early access programme in France. Horm Res Paediatr. 2022;95(Suppl 2):308.
Cormier-Daire V, Edouard T, Isidor B, et al. Real-world safety and effectiveness of vosoritide: Results from an early-access program in France. Presented at the 2023 ESPE European Society for Paediatric Endocrinology, 21–23 September 2023, The Hague, Netherlands.
Palm K, Bechthold-Dalla Pozza S, Gausche R, et al. Real-world data in children with achondroplasia after licensing of vosoritide. Horm Res Peadiatr. 2022;95(Suppl 2):151.
Kunkel P, Al Halak M, Bechthold-Dalla Pozza S, et al. Multidisciplinary approach in achondroplasia – real world experience after drug approval of vosoritide. Presented at the 2023 ESPE European Society for Paediatric Endocrinology, 21–23 September 2023, The Hague, Netherlands.
Voxzogo Summary of Product Characteristics 2021. https://www.ema.europa.eu/en/documents/product-information/voxzogo-epar-product-information_en.pdf . Accessed 05 May 2023
Voxzogo US Prescribing Information (2021, November). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf Accessed 05 May 2023.
Savarirayan R, Ireland P, Irving M, et al. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022;18:173–89.
doi: 10.1038/s41574-021-00595-x
pubmed: 34837063
Cormier-Daire V, AlSayed M, Ben-Omran T, et al. The first European consensus on principles of management for achondroplasia. Orphanet J Rare Dis. 2021;16:333.
doi: 10.1186/s13023-021-01971-6
pubmed: 34332609
pmcid: 8325831
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Health Care Utilization and Adults with Disabilities. Health-Care Utilization as a Proxy in Disability Determination. Washington (DC): National Academies Press (US); 2018.
Katz AL, Webb SA, AAP Committee on Bioethics. Informed consent in decision-making in pediatric practice. Pediatrics. 2016;138:e20161485.
doi: 10.1542/peds.2016-1485
pubmed: 27456510
NiMhurchadha S, Butler K, Argent R, et al. Parents’ experience of administering vosoritide: a daily injectable for children with achondroplasia. Adv Ther. 2023. https://doi.org/10.1007/s12325-023-02496-z .
doi: 10.1007/s12325-023-02496-z
pubmed: 37017912
pmcid: 10129947
Protocole d’utilisation thérapeutique et de recueil de données (PUT-RD). Accès précoce—VOXZOGO (vosoritide). https://has-sante.fr/plugins/ModuleXitiKLEE/types/FileDocument/doXiti.jsp?id=p_3304523 Accessed 17 May 2023.
Voxzogo exclusion criteria: an extension study to evaluate the efficacy and safety of BMN 111 in children with achondroplasia, 2018. https://www.clinicaltrials.gov/ct2/show/NCT03424018?term=302&cond=BMN111&draw=2&rank=1 Accessed 05 May 2023.
Greulich W, Pyle I. Radiographic atlas of skeletal development of the hand and wrist. London: Stanford University Press; 1959.
doi: 10.1097/00000441-195909000-00030